๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 57 Beijing 54 Guangzhou 48 Hangzhou 27 Fuzhou 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.4 Jiangsu HengRui Medicine Co., Ltd.3 Haisco Pharmaceutical Group Co., Ltd.2 Shanghai Hengrui Pharmaceutical Co., Ltd.2
Site location
Shanghai57 Beijing54 Guangzhou48 Hangzhou27 Fuzhou23
All 64 locations
Target enrolment
to

Trials with a site in Shanghai

57 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors
NCT07719920Advanced Solid Tumors
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1
99
Shanghai
2026-09-10
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Recruiting
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors
NCT07700160Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
230
Beijing, Shanghai, Hangzhou
2026-07-30
Recruiting
A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
NCT07622524Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1
310
Shanghai
2026-07-16
Not yet open
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
NCT07699757Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
DrugsHSK41959·Cisplatin/carboplatin·Sintilimab·Nab-paclitaxel
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
258
Shanghai
2026-07
Recruiting
SKB118 Injection in Advanced Solid Tumors
NCT07586943Advanced Solid Tumors
DrugsSKB118·Sacituzumab tirumotecan
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
530
Shanghai
2026-06-01
Not yet open
A Phase โ…  Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
A Study of HDM2024 in Participants With Advanced Solid Tumors
NCT07539285Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
63
Shanghai
2026-04-10
Recruiting
SKB105 for Injection in Advanced Solid Tumors
NCT07380386Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
256
Beijing, Shanghai
2026-03-05
Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
NCT07321574SCLC, Extensive Stage, Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
NCT07310134Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1
80
Shanghai
2025-12-26
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
NCT07596693Advanced Solid Tumors
DrugKXV01 TCR Lentinvivo
TCRx Therapeutics Co.Ltd
Phase 1
30
Shanghai
2025-12-19
Recruiting
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
NCT07702162Advanced Solid Tumors, Cancer
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
49
Fuzhou, Shanghai
2025-11-14
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
NCT07241936Advanced Solid Tumors
DrugsDP303c·SYS6043·SYS6010·Sirolimus
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
444
Shanghai
2025-11-13
Recruiting
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
NCT06144671Advanced Solid Tumors
DrugsGT201·Aldesleukin
Grit Biotechnology
Phase 1/2
78
Shanghai, Chengdu
2025-11-01
Not yet open
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787Advanced Solid Tumors
DrugsIMM01·IMM2510
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2
104
Shanghai
2025-10-15
Recruiting
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
NCT07164950Urothelial Carcinoma, Advanced Solid Tumors, Chemotherapy-Induced Peripheral Neuropathy, Antibody-drug Conjugates
Sheng Zhang
Not applicable
58
Shanghai
2025-08-30
Recruiting
A Study of HDM2012 in Patients With Advanced Solid Tumor
NCT07100249Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
129
Shanghai
2025-08-06
Recruiting
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT07060989Advanced Solid Tumors
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Shanghai
2025-08-04
Not yet open
A Study of QLS5133 Monotherapy in Advanced Solid Tumors
NCT07061639Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
212
Shanghai
2025-07
Recruiting
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
NCT06993870Advanced Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2025-06-16
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Not yet open
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
NCT06963502Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
DrugsPlatinum (cisplatin·HS-10370·HS-20117·HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
A Study of HDM2005 in Patients With Advanced Solid Tumor
NCT07004296Advanced Solid Tumors
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
72
Shanghai
2025-05-29
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2
130
Chongqing, Jinan, Shanghai
2025-04-30
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
NCT06968572Advanced Solid Tumors
DrugHSK41959
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
245
Guiyang, Nanjing, Shanghai
2025-04-11
Recruiting
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
NCT07744763Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
260
Shanghai
2025-03-28
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
A Phase โ…  Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors
NCT07229898Advanced Solid Tumors
DrugGEN-725
Henan Genuine Biotech Co., Ltd.
Phase 1
48
Harbin, Jinan, Shanghai, Xinxiang
2025-01-07
Recruiting
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
NCT07046650Advanced Solid Tumors
Sheng Zhang
Phase 2
84
Shanghai
2025-01-01
Recruiting
A Study of HDM2006 in Patients With Advanced Solid Tumor
NCT07377591Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
48
Shanghai
2024-12-31
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06686745Advanced Solid Tumors
DrugOlaparib
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Shanghai, Chongqing
2024-12-06
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
NCT06605222Advanced Solid Tumors
DrugSHR-7787
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
201
Shanghai
2024-10-04
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
NCT06520488Advanced Solid Tumors
DrugHRS-4642
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
118
Shanghai
2024-08-09
Recruiting
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970Advanced Solid Tumors
DrugMRG006A
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836Advanced Solid Tumors, HCC
DrugIMM2510
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Recruiting
A Study of SKB518 in Patients With Advanced Solid Tumors
NCT06428331Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2024-07-04
Recruiting
AMT-676 in Patients With Advanced Solid Tumors
NCT06400485Advanced Solid Tumors
DrugAMT-676
Multitude Therapeutics Inc.
Phase EARLY_PHASE1
24
Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou
2024-06-18
Recruiting
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
NCT06445517Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited
Phase 1
60
Beijing, Nanchang, Shanghai, Tianjin
2024-04-25
Recruiting
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT06336707Advanced Solid Tumors
DrugsHS-20089·Cisplatin/carboplatin·Adebrelimab·Bevacizumab
Hansoh BioMedical R&D Company
Phase 1
1,048
Shanghai
2024-04-11
Recruiting
A Study for HSK39775 in Participants With Solid Tumors
NCT06314373Advanced Solid Tumors
Xizang Haisco Pharmaceutical Co., Ltd
Phase 1/2
243
Shanghai
2024-03-07
Recruiting
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
NCT06158477Advanced Solid Tumors
Chengdu JOYO pharma Co., Ltd.
Phase 1
75
Shanghai
2024-01-01
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT05867420Advanced Solid Tumors
DrugsFruquintinib·Docetaxel·Bevacizumab·Paclitaxel
AskGene Pharma, Inc.
Phase 1/2
594
Beijing, Shanghai
2023-08-02
Active, closed
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
NCT05914376Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709Advanced Solid Tumors
DrugSHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Active, closed
A Phase I Clinical Study of the Safety๏ผŒ Tolerability๏ผŒPharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
NCT05781048Advanced Solid Tumors
DrugHRS-6209
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Recruiting
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
NCT05823285Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Recruiting
A Study of GC101 TIL in Advanced Solid Tumors (TR)
NCT04967833Advanced Solid Tumors
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
20
Shanghai
2021-04-22
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

47 of the 57 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 6 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 57 studies
PhaseStudiesRecruitingShare
Phase 1312554.4%
Phase 1/2201635.1%
Phase 2335.3%
Phase EARLY_PHASE1223.5%
Not applicable111.8%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.55
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.44
Jiangsu HengRui Medicine Co., Ltd.32
Haisco Pharmaceutical Group Co., Ltd.21
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.21
Qilu Pharmaceutical Co., Ltd.21
Shanghai Hengrui Pharmaceutical Co., Ltd.22
Sheng Zhang22
VelaVigo Bio Inc21
AbbVie10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.